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In the development of the adult lead manage-
ment guidelines (see Kosnett et al. 2007), a
number of health outcomes adversely affected
by lead exposure were discussed. Cognitive
function was an important consideration of
because of the growing number of studies in
this area and increasing concern that cogni-
tive function in adulthood may be affected by
relatively low lead doses. In this article, we
systematically review recent evidence con-
cerning recent and cumulative lead dose and
adult cognitive function. 
Measurement of lead dose. In reviewing
studies of the health effects of lead, it is criti-
cal to understand the available lead biomark-
ers in terms of how they represent external
exposure (in terms of timing, duration, mag-
nitude, and accumulation); how they are
inﬂuenced by metabolic factors (organ distri-
bution, compartmental dynamics, the influ-
ence of physiologic factors); and how the
combination of these considerations affects
inferences regarding the health effects of lead
(Hu et al. 2007). We conclude from these
important methodologic issues that the most
informative recent epidemiologic studies of
lead’s impact on health are those that were
able to derive estimates of both recent and
cumulative lead exposure for each study par-
ticipant. To achieve this end with the greatest
precision and accuracy, such studies have
incorporated measurements of lead in both
blood (whole blood, using standard chemical
assays such as graphite furnace atomic absorp-
tion spectroscopy) and bone [using noninva-
sive in vivo K-shell X-ray fluorescence
(KXRF) instruments]. 
Blood lead levels measured in epidemio-
logic studies with valid instruments and stan-
dardized calibration and quality control
procedures have been reported in the litera-
ture for > 35 years. Bone lead levels measured
by in vivo KXRF were begun in some
research laboratories in the 1980s, but it was
not until the mid-1990s that reports began to
emerge of KXRF-measured bone lead levels
in relation to potential health indicators from
epidemiologic studies with sufficient sample
sizes (for example, ≥ 100 subjects) to have
substantial statistical power. Thus, in this
review we summarize all studies to date that
measure cognitive function and both blood
and bone lead levels (or acceptable surrogate
for cumulative lead dose). 
Published reviews of relevance to this
review. We begin our review with a discus-
sion of three other reviews on the topic of
lead dose and cognitive function (Balbus-
Kornfeld et al. 1995; Goodman et al. 2002;
Meyer-Baron and Seeber 2000). Balbus-
Kornfeld et al. (1995) reviewed the evidence
on cumulative lead exposure and cognitive
function from studies published from 1976
to 1991. Among 21 unique studies that were
identiﬁed at the time of the authors’ review,
none used a biomarker of cumulative dose.
Of the four longitudinal studies, all were
small (mean sample size in the analysis of
47 lead-exposed subjects), with relatively low
follow-up rates and relatively short durations
of follow-up. The authors thus concluded
that the available literature provided inade-
quate evidence to conclude whether cumula-
tive exposure or absorption of lead adversely
affected cognitive function in adults. 
Goodman et al. (2002) and Meyer-Baron
and Seeber (2000) are reviewed here because
they had generally opposite conclusions,
which led to considerable controversy and dis-
cussion (Goodman et al. 2001; Schwartz et al.
2002; Seeber and Meyer-Baron 2003; Seeber
et al. 2002). The Goodman et al. (2002) arti-
cle was funded by the German Battery
Association, apparently in anticipation of con-
sideration in Germany of lowering the blood
lead standard in lead workers (Seeber and
Meyer-Baron 2003). Goodman et al. (2002)
reviewed 22 studies published between 1974
and 1999 with the expressed aim of evaluating
associations between moderate blood lead lev-
els and neurobehavioral test scores after occu-
pational exposure to lead. Studies were
included if the central tendency for blood lead
levels was < 70 µg/dL, the numbers of exposed
and unexposed were reported, and test score
arithmetic means and measures of variability
were reported for exposed and unexposed
workers (Goodman et al. 2002). The authors
concluded that none of the individual studies
were conclusive or adequate in providing
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OBJECTIVE: We review empirical evidence for the relations of recent and cumulative lead dose with
cognitive function in adults. 
DATA SOURCES: A systematic search of electronic databases resulted in 21 environmental and occu-
pational studies from 1996 to 2006 that examined and compared associations of recent (in blood)
and cumulative (in bone) lead doses with neurobehavioral outcomes.
DATA EXTRACTION: Data were abstracted after consideration of exclusion criteria and quality assess-
ment, and then compiled into summary tables. 
CONCLUSIONS: At exposure levels encountered after environmental exposure, associations with bio-
markers of cumulative dose (mainly lead in tibia) were stronger and more consistent than associa-
tions with blood lead levels. Similarly, in studies of former workers with past occupational lead
exposure, associations were also stronger and more consistent with cumulative dose than with
recent dose (in blood). In contrast, studies of currently exposed workers generally found associa-
tions that were more apparent with blood lead levels; we speculate that the acute effects of high,
recent dose may mask the chronic effects of cumulative dose. There is moderate evidence for an
association between psychiatric symptoms and lead dose but only at high levels of current occupa-
tional lead exposure or with cumulative dose in environmentally exposed adults. 
KEY WORDS: adults, blood, bone, cognitive function, lead, neurobehavior. Environ Health
Perspect 115:483–492 (2007). doi:10.1289/ehp.9786 available via http://dx.doi.org/ [Online
22 December 2006]information on the effects of lead on cognitive
function and called for prospective studies that
would evaluate cognitive function before and
after exposure. There was no discussion about
whether examining relations of blood lead lev-
els with cognitive function was the most rele-
vant question if the hypothesis was that
cumulative lead dose was most important to
cognitive function. There was little explicit
discussion of whether lead may have acute
effects as a function of recent dose, and
chronic effects as a function of cumulative
dose, or how this could be assessed by review
of epidemiologic studies. 
Meyer-Baron and Seeber (2000) per-
formed a meta-analysis of 12 studies using
selection criteria similar to Goodman et al.
(2002) but also with the requirement for
reporting means and standard deviations of
dependent variables (Meyer-Baron and Seeber
2000). They concluded that there were obvi-
ous neurobehavioral deﬁcits at current blood
lead levels < 40 µg/dL. Again, the focus was on
associations with blood lead levels, and there
was little formal discussion about which lead
biomarker was most relevant to hypotheses
about how cumulative lead dose may inﬂuence
cognitive function. Thus, this is the ﬁrst review
to evaluate epidemiologic studies that distin-
guish between the acute effects of recent dose
from the chronic effects of cumulative dose.
Methods
Methodologic considerations for relations of
lead dose and cognitive function. Many
methodologic issues of relevance to the epi-
demiologic investigation of lead and cognitive
function have been addressed elsewhere in
this mini-monograph (Hu et al. 2007). When
evaluating the associations of cumulative lead
dose with cognitive function, it is important
to acknowledge that nonoccupational sources
of lead exposure were present for all members
of the general population, including lead
workers throughout the early part of this cen-
tury until public health interventions progres-
sively removed lead from gasoline and many
consumer products during the 1970s and
1980s (Agency for Toxic Substances and
Disease Registry 1999; Annest et al. 1983;
Pirkle et al. 1998). Lead remains a low-level
and ubiquitous neurotoxicant in the environ-
ment and is found in measurable levels in all
individuals (Hoppin et al. 1995). Thus, cur-
rent tibia lead levels represent a mix of occu-
pational and environmental exposures. This
review does not try to determine whether the
main source of lead was occupational or envi-
ronmental but rather focuses on whether lead
in blood or bone is associated with adverse
cognitive outcomes in adults. 
Identiﬁcation of studies. We conducted a
systematic literature review of the association
between blood and bone lead biomarkers and
cognitive functioning in adults. Our aim was
to select studies that compared markers of
both recent and cumulative lead dose in their
relations with cognitive function. Both occu-
pationally and environmentally exposed adult
populations were included. We searched the
PubMed (National Library of Medicine
2006) and PsycINFO databases (American
Psychological Association 2006) for epidemi-
ologic studies using keywords such as blood,
bone, lead, cumulative, cognitive, and neu-
robehavior. There were no date or language
restrictions. From the identiﬁed publications
and relevant review articles, we examined ref-
erence lists to locate additional studies that
measured both recent and cumulative lead
dose. This includes blood lead levels, bone
lead levels, or a surrogate measure of cumula-
tive lead dose such as integrated blood lead
(IBL), area under the curve of blood lead lev-
els over time, or the product of blood lead
level and employment time. Studies were not
considered for the review if they a) contained
no original research, b) were conducted on
nonhuman subjects, c) were case reports,
d) contained no standardized neurocognitive
assessment outcomes, or e) lacked measures of
both recent and cumulative lead dose.
Data abstraction. We abstracted data
from articles meeting the selection criteria.
Study quality was assessed with the following
criteria: a) exposure was assessed at an indi-
vidual level; b) exposure was assessed with a
biomarker; c) cognitive outcomes were objec-
tive, standardized tests; d) statistical adjust-
ment for potential confounders including age,
sex (in studies with both men and women),
and education; e) data collection was similar
in exposed and nonexposed participants;
f ) time period of study was the same in
exposed and nonexposed participants; and
g) there was a detailed description of the
approach to data analysis. We decided not to
try to derive a pooled estimate across studies
of the associations of lead dose biomarkers
with cognitive function because of differences
in methods for subject selection, blood and
bone lead measurements, neurobehavioral
outcomes, approach to regression modeling,
and presentation of results across studies.
Pooled estimates from metaanalysis also can
be highly influenced by decisions regarding
how and whether to pool certain results. We
thus decided to present details for each study
and discuss them in turn. 
Results
Overview of evidence. We identified three
main types of studies that reported cross-sec-
tional or longitudinal associations of blood
and bone lead levels with cognitive function.
These were of a) environmentally exposed
individuals in the general population, b) work-
ers with current occupational exposure, and
c) former lead workers without current occu-
pational exposure to lead. We have summa-
rized these studies in Table 1, provided details
in Table 2, and discuss them in order below. 
Studies of adults without occupational
lead exposure. We identiﬁed six articles from
three studies [i.e., residents near a lead smelter,
the Normative Aging Study (NAS), and the
Baltimore Memory Study] that evaluated sub-
jects with mainly environmental exposure to
lead (Tables 1 and 2). One study of young
adults 19–29 years of age compared 257 indi-
viduals with high childhood blood lead levels
from exposure 20 years previously from a lead
smelter to 276 age- and sex-matched controls.
This study found impairment on many cogni-
tive tests among the highly exposed group, but
minimal association on most tests with tibia
lead levels measured during young adulthood
(Stokes et al. 1998). 
Four articles from the NAS reported asso-
ciations of blood and bone lead levels in a
cohort of older men. One of these articles
(Payton et al. 1998) was a first report that
examined scores on a large battery of cogni-
tive tests of a small sample (n = 141) of NAS
participants. This was subsequently followed
up with a report on a much larger number of
NAS participants (n = 1,089 with blood lead
levels and n = 760 with bone lead levels,
Shih et al.
484 VOLUME 115 | NUMBER 3 | March 2007 • Environmental Health Perspectives
Table 1. Study characteristics of 21 articles on adult
cognitive function (1996–2006) with biomarker meas-
ures of recent and cumulative lead dose.
No. (percent of total 
Article feature no. of papers)
Main source of lead exposure
Occupational 15 (71.4)
Environmental 6 (28.6)
Demographics
Age (years)
Mean < 50 15 (71.4)
Mean ≥ 50 6 (28.6)
Sex
> 80% male 16 (76.2)
≤ 80% male 5 (23.8)
Race/ethnicity
Mixed 1 (4.8)
Not mixed (> 80% one group) 14 (66.6)
Not reported 6 (28.6)
Type of lead dosea
Blood lead (µg/dL)
Peak/median/mean < 10 10 (47.6)
Peak/median/mean ≥ 10 11 (52.4)
Tibia lead (µg/g)
Mean < 25 9 (42.9)
Mean ≥ 25 5  (28.6)
Patella lead (µg/g)
Mean < 25 1 (4.8)
Mean ≥ 25 4  (19.0)
Cumulative dose measure
Tibia 13 (61.9)
Patella 5 (28.6)
Integrated blood lead 8 (38.1)
Other 3 (14.3)
aTime-integrated blood lead was not summarized here
because of differences in the way it is calculated for each
study.412–515 of whom took different tests twice
approximately 3.5 years apart) (Weisskopf
et al. 2007). Cross-sectional analyses in the
original report found that increased blood
lead levels across a relatively low range of
levels [mean ± SD = 5.5 ± 3.5 µg/dL) were a
stronger predictor, compared with tibia or
patella lead levels, of poorer performance on
tests of speed, verbal memory, vocabulary,
and spatial copying skills. However, this was
not confirmed in the larger, cross-sectional
analysis, except possibly for scores on a vocab-
ulary test (Weisskopf et al. 2007). Conversely,
in longitudinal analyses, the larger study
found more decline over time on almost all
cognitive tests associated with both higher
patella and higher tibia bone lead levels, with
the associations reaching statistical signifi-
cance for pattern comparison and spatial
copying skills. An earlier, similar longitudinal
analysis by Weisskopf et al. (2004) in this
same population reported that patella lead
levels were significantly associated with a
decline in Mini-Mental State Examination
(MMSE; Folstein et al. 1975) score over time.
A slightly smaller association was observed with
tibia lead levels, whereas no association was
observed with blood lead levels. In cross-sec-
tional analyses of the same population, higher
blood lead levels were a stronger predictor of
poorer performance on the MMSE, as were
higher patella and tibia bone lead levels
(Payton et al. 1998; Wright et al. 2003). 
In a study of almost 1,000 persons
50–70 years of age randomly selected from
the general population in the Baltimore
Memory Study (BMS), a cross-sectional
analysis showed that relatively low current
blood lead levels were not associated with
cognitive domain scores. However, moderate
tibia lead levels (mean ~ 19 µg/g) were signiﬁ-
cantly associated with worse performance in
all seven cognitive domains (Shih et al. 2006).
Thus, in the environmental studies of older
adults, the most consistent findings across
Blood lead, bone lead, and adult cognitive function
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Table 2. Detailed summary and main ﬁndings of studies on cognitive function with recent and cumulative lead dose biomarkers.
Percent male Race/ Primarily Lead dose Covariates
Sample [mean age in  ethnicity Source of  current/ measure adjusted for
Author  size (no.) Design years (SD)] (%) Pb exposure past exposure [mean (SD)] outcome measures Summary of ﬁndings
Nonoccupational lead exposure
Stokes  257 (E) XS 47.7% (E) White (E) Resided near lead  Past (E) Blood: (E) 2.9 (3.3) Age, education, sex,  Dichotomized exposure group associated 
et al.  276 (R) 24.3 (3.2) 98 smelter during  ~ 20 years  (R) 1.6 (1.4) height, BMI with neurobehavioral outcomes, but no 
1998  49.6% (R) White (R) childhood (E) prior Tibia: (E) 4.6 (range,  Battery of tests— signiﬁcant associations between tibia 
24.2 (3.0) 94.2 Random sample  –28.9 to 37) 6 domains lead and neurobehavioral outcomes
of licensed  (R) 0.6 (range, 
drivers (R) –46.4 to 17.4)
Payton 141 XS 100% White Environmental Past Blood: 5.5 (3.5) Age, education Blood lead signiﬁcant predictor of 
et al. 66.8 (6.8) 94 (Normative  Tibia: 22.5 (12.2) Battery of tests— performance on speed, memory, spatial 
1998  Aging Study) Patella: 31.7 (19.2) 8 domains copying, and vocabulary
Tibia lead associated with pattern memory 
and spatial copying
Patella lead had less signiﬁcant 
relationships with test scores than tibia 
lead
Wright  736 blood, XS 100% White Environmental Past Blood: 4.5 (2.5) Age, education, alcohol  Blood lead OR = 1.21 (95% CI, 1.07–1.36) 
et al. tibia, 68.2 (6.9) 94 (Normative  Tibia: 22.4 (15.3) intake for MMSE < 24
2003  patella  Aging Study) Patella: 29.5 (21.2) MMSE score < 24 Tibia lead OR = 1.02 (95% CI, 1.00–1.03) 
lead for MMSE < 24
295 blood  Patella lead OR = 1.02 (95% CI, 1.00–1.04) 
only for MMSE < 24
Patella and blood lead levels modiﬁed the 
effect of increasing age on MMSE score
Weisskopf 466 L 100% White Environmental Past Median [IQR] Age, smoking, education,  Null association between baseline 
et al. F/U = 61.9% 67.4 (6.6) 94 (Normative  Blood: 4 [3, 5] alcohol intake, and  blood lead and change in MMSE
2004  Aging Study) Tibia: 19 [12, 26] years between MMSE  Patella lead signiﬁcantly associated with 
Patella: 23 [15, 35] tests decline in MMSE (an IQR higher patella
Change in MMSE score lead = ~ 5 years of aging on baseline 
MMSE)
Tibia lead similar to patella but not quite 
signiﬁcant
Weisskopf 1,089 blood XS  100%  White Environmental Past Median [IQR] Age, age squared,  XS analysis: blood lead signiﬁcant 
et al.  761 tibia and 68.7 (7.4) 98 (Normative  Blood: 5 [3, 6] education, smoking,  predictor of performance on vocabulary 
2007 760 patella L Aging Study) Tibia: 20 [13, 28] and alcohol intake test
Patella: 25 [17, 37] Battery of 10 cognitive  L analysis: tibia lead associated with 
tests pattern comparison
L analysis: patella lead associated with 
pattern comparison and spatial copying
Shih, et al.  994 XS 34.1% African  Environmental Past Blood: 3.5 (2.2) Series of 5 models  Tibia lead was consistently associated 
2006  59.4 (6.0) American (Baltimore  Tibia: 18.7 (11.2) adjusting for age, sex,  with lower test scores in all 7 cognitive 
40.1 Memory Study) APOE e4 allele, domains 
education, race, wealth Blood lead was not associated with any 
Scores in 7 cognitive  cognitive domain
domains
Occupational lead exposure
Lindgren  467 XS 100% White Canadian lead  370 currently  Blood: 36 Age, education,  Lack of association between 
et al. 43.4  (11) 100 smelter employed IBL
a: mean across  language, depressive  neuropsychologic performance and 
1996  (Canada Lead  97 previously  groups,  scale score, head  blood lead or TWA
Study) employed 268.6–1,227.7 injury, neurological  IBL related to visuomotor skills, 
TWA
b: mean across  disorder, alcohol use psychomotor speed and dexterity, motor 
groups, 26.1–52.8 Battery of tests— speed, and verbal memory performance
8 domains
Continued, next pagestudies are associations between bone lead
levels and cognitive function. The associa-
tions in the BMS were cross-sectional,
whereas the predominant associations in the
NAS were with change in cognitive function
over time, although a significant cross-sec-
tional association with MMSE score was also
observed in this sample. Taken together, these
data suggest that at environmental exposure
levels, the effects of cumulative exposure are
more pronounced than recent effects of cur-
rent exposure. The absence of associations in
the Stokes et al. (1998) study could be
because of the younger age of studied sub-
jects, the very low current blood and tibia
lead levels, or the inadequacy of tibia lead in
the third decade of life to estimate early life
dose (Hoppin et al. 2000). 
Studies of occupationally exposed workers.
Fifteen articles were identified of workers
with current or past occupational exposure to
lead. Eight of these studies used a surrogate
measure of cumulative lead dose (i.e., IBL)
rather than a direct measure of lead in bone.
Among these studies, which compared blood
and IBL lead dose, when the lead exposure
was primarily current (e.g., relatively high
blood lead levels), most studies found an asso-
ciation between increasing blood lead values
and worse cognitive function (Barth et al.
2002; Bleecker et al. 1997; Lucchini et al.
2000). However, studies in which the exposure
was primarily in the past demonstrated that
surrogate measures of cumulative dose were a
stronger predictor of worse cognitive function
compared with blood lead levels (Bleecker
et al. 2005; Chia et al. 1997; Lindgren et al.
1996). Studies that used bone lead levels as a
direct indicator of retained cumulative lead
dose are summarized below. 
One study of currently exposed lead
workers in South Korea (n = 803) found
strong and consistent associations of blood
lead levels with worse cognitive function after
adjustment for covariates, but tibia lead levels
were not as consistently associated (Schwartz
et al. 2001). The same null ﬁndings for bone
lead levels were observed in two smaller
Shih et al.
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Table 2. Continued.
Percent male Race/ Primarily Lead dose Covariates
Sample [mean age in  ethnicity Source of  current/ measure adjusted for
Author  size (no.) Design years (SD)] (%) Pb exposure past exposure [mean (SD)] outcome measures Summary of ﬁndings
Bleecker  80 XS 100 White Canadian lead  Current Blood: 26.4 (7.1) Age, education Signiﬁcant amount of variance in verbal 
et al.  44.1 (8.4) 100 smelter 4–26 years IBLa: 903.1 (305.9) Battery of tests— memory performance accounted for only 
1997 (Canada  Lead  of  exposure TWAb: 42.3 (8.4) 5 domains by measures of blood lead and TWA
Study) Tibia: 41.0 (24.4) Visuomotor ability had signiﬁcant variance 
accounted for by measures of TWA, IBL 
and tibia lead
Chia et al.  50 (E) XS 100 100%  Lead battery  Current Blood: (E) 37.1  Age, education,  E and NE groups signiﬁcantly different in 
1997  97 (NE) (E) 35.7  Asian  manufacturing  (range, 13.2–64.6) smoking history,  tests involving motor dexterity, and 
(10.6) (48  factory (E) (NE) 6.14  ethnic groups,  visuomotor and psychomotor speed
(NE) 33.9  Chinese)  Vehicle  (range, 2.4–12.4) drinking habits Cumulative blood associated with Digit 
(3.7) (E) maintenance CumPbc: (E) 175.9  Battery of tests— Symbol and Trail Making Part A scores
100 workshop  (NE) (range, 10.0–1146.2) 5 domains  Cumulative blood lead a stronger predictor 
Asian  of neurobehavioral effects than 
(43  concurrent blood lead levels
Chinese) 
(NE)
Osterberg  38 (E) XS 100 NR Secondary lead  Current  Current blood leadd: Matched on age,  Neither blood (current or peak) lead nor 
et al.  19 (NE) (E) median: smelter— 2–35 years (E) median, 1.8  education, job level ﬁnger bone lead levels were associated 
1997  41.5 inorganic lead (E) of exposure (range, 0.9–2.4) Battery of tests— with any neurobehavioral measures
Nearby mechanical  (NE) median, 0.18  5 domains
manufacturing (range,  0.07–0.34)
plant (NE) Peak blood leadd: 
(E) median, 3.0 
(range, 2.2–4.3)
CBLIe: 
(E) median, 233 
(range, 74–948)
Finger bone:
(E) median, 32 
(range, 17–101)
(NE) median, 4 
(range, –19 to 18)
Hanninen  54 XS 79.6 NR Helsinki lead acid  Past Low blood leadd:  Age, sex, education None of the bone lead measures were 
et al.  Low blood  battery factories 12.3, 20.5  TWAf: 1.4 (0.3) Battery of tests— signiﬁcantly associated with any test 
1998  lead years of  Peak blood leadd: 6 domains scores
41.7 (9.3) exposure  1.9 (0.4) The low blood lead group showed 
High blood  (means  IBLg: 15.7 (9.5) associations between historical blood 
lead across  Calcaneus: 78.6  lead measures and visuospatial, 
46.6 (6.2) groups) (62.4) mg/kg  visuomotor, attention and verbal 
Tibia: 19.8 (13.7)  comprehension performance
mg/kg  The high blood lead group had worse 
High blood leadd performance than the low blood lead 
TWAf : 1.9 (0.4) group on tests of attention (Digit Symbol), 
Peak blood leadd:  visual memory (memory for design), and 
3.3 (0.7) visuoperception (embedded ﬁgures)
IBLg: 39.2 (18.5)
Calcaneus: 100.4 
(43.1) mg/kg 
Tibia: 35.3 (16.6) 
mg/kg 
Continued, next pagestudies, one with male smelter workers (n =
57) in whom finger bone (mixed trabecular
and cortical tissue) lead levels were measured
(Osterberg et al. 1997). The second article
describes the study of a sample of 54 storage
battery workers in whom tibia and calcaneus
lead levels were measured (Hanninen et al.
1998). This is the only study published to
date to report an association between IBL and
cognitive outcomes in which there was a lack
of an association with bone lead levels. Both
these studies used early XRF techniques (e.g.,
KXRF with cobalt-57) with higher limits of
detection that have not been commonly used
since, and this use makes the findings more
difﬁcult to interpret. Bleecker et al. (1997), in
a study similar to the one by Schwartz et al.
(2001), reported stronger and more consis-
tent associations of blood lead measures and
neurobehavioral test performance compared
to tibia lead levels. 
In the South Korean lead workers with
current occupational exposure, a longitudinal
analysis was performed to separate recent lead
dose (measured as blood lead levels) from
cumulative lead dose (measured as tibia lead
levels), and acute effects from chronic effects
in 575 subjects with complete data across the
three study visits (Schwartz et al. 2005). The
authors reported significant cross-sectional
associations of blood lead levels with lower
executive ability and manual dexterity test
scores, with some evidence also for a longitu-
dinal association of changes in blood lead lev-
els with neurobehavioral decline. Tibia lead
levels were more consistently associated with
longitudinal declines in manual dexterity,
executive abilities, neuropsychiatric symp-
toms, and peripheral sensory functioning than
change in blood lead levels. The authors con-
cluded that lead was associated with worse
cognitive function in two ways: an acute
effect of recent dose and a chronic effect of
cumulative dose. The authors also discussed
that contrasting associations with blood and
tibia lead levels could be due to the following:
a) tibia and blood lead levels are biologically
related and blood lead is in equilibrium with
Blood lead, bone lead, and adult cognitive function
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Table 2. Continued.
Percent male Race/ Primarily Lead dose Covariates
Sample [mean age in  ethnicity Source of  current/ measure adjusted for
Author  size (no.) Design years (SD)] (%) Pb exposure past exposure [mean (SD)] outcome measures Summary of ﬁndings
Stewart  543 XS 100 White Eastern U.S.  Past Tibia: 14.4 (9.3) Age, race, education,  Peak tibia lead strongest and most 
et al.  38% were  92.8 tetraethyl  Mean of  Peak tibia: 23.7 (17.4) testing, lead measures,  consistent predictor of test scores: 
1999  ≥ 60  and tetramethyl  17.8 years  years since last  manual dexterity, executive ability, verbal 
years of age  lead manu- since last  exposure, depressive  intelligence and memory 
(range, 40–70) facturing  exposure at  score, tobacco,  Current tibia lead also associated with 
facility time tibia  alcohol consumption,  same domains except verbal memory
(U.S. Organolead  lead  visit number On average, an increase in 22 µg/g peak 
Study) obtained Battery of tests— tibia lead was equivalent to an increase 
8 domains in 5 years of age
Lucchini  66 (E)  XS 100 NR Lead accumulators  Current Blood: 27.5 (11.0) (E) Age, education, alcohol,  Neurologic symptoms 
et al. 86 (NE) (E) 40.1 (8.7)  and bullet  1–33 years  8.1 (4.5) (NE) smoking, coffee intake (neuropsychologic, sensory motor) more 
2000  (NE) 42.6 (8.8) manufacturers  of exposure IBLa: 409.8 (360.8) (E) Neurological symptoms  frequent, and decreased sensitivity to 
and 2 lead  TWAb: 31.7 (14.1) (E) and a battery of 4  visual contrast sensitivity test in exposed 
smelters in  neurobehavioral tests workers. These associations are with 
Northern Italy (E) current blood lead and not cumulative 
Hospital (NE) lead measures (on a E vs. NE comparison, 
but not individual level)
No differences between groups on 
neurobehavioral tests
Signiﬁcant differences between low and 
high IBL groups on neuropsychologic 
scores
Schwartz  535 (E) L 100 White  Eastern U.S.  Past Blood: 4.26 (2.6) (E) Frequency matched on  Exposed workers showed greater annual 
et al.  F/U = 99.8% 55.6 (7.4)  93.1  tetraethyl  Mean of 16  Tibia: 14.4 (9.3) (E) age, education and race declines than controls in verbal memory, 
2000  with 1 +  at ﬁrst visit (E) and tetramethyl  years since  Peak tibia: 22.6  Battery of tests— visuoconstruction domains
visit 58.6 (7.0) (NE) lead manu- exposure at  (16.5) (E) 8 domains Peak tibia lead, but not blood lead, 
118 (NE) facturing  last baseline consistently predicted declines in test 
F/U = 91.6% facility (E) scores: symbol digit, verbal and visual 
with 1 +  Community-based  memory, motor speed, and executive 
visit random  sampling  ability 
from residential  On average, an increase of 15.7 µg/g peak 
areas of former  tibia lead was equivalent to annual test 
lead workers (NE) decline to ≥ 5 years of age at 
(U.S. Organolead  baseline
Study)
Schwartz  803 (E) XS (E) 79.6 Asian  Battery, lead oxide  Current Blood: 32 (15) (E) Age, sex, education,  Blood lead was a better predictor of tests 
et al.  135 (NE) 40.4 (10.1) 100 or car radiator  (8 retired) 5.3 (1.8) (NE) each lead measure,  of executive abilities, manual dexterity, 
2001  (NE) 91.9 manufacturing Tibia: 37.1 (40.3) (E)  height, BMI and peripheral motor strength than tibia 
34.5 (9.1) and secondary  5.8 (7.0) (NE) Battery of tests— or DMSA-chelatable lead
lead smelters (E) 9 domains On average, an increase of 5 µg/dL blood 
Air conditioner  lead was equivalent to an increase of 
manufacturing  1.05 years in age
or university (NE)
(Korea Lead Study) 
Barth et al.  47 (E) XS 100 NR Storage-battery  Current Blood lead: Age, years of education,  Current blood lead levels, but not 
2002  53 (NE) 39.5 (9.7) (E) plant (E) 0.1–36.1  30.8 (11.2) (E) verbal intelligence,  cumulative blood lead levels, were 
39.3 (8.4) (NE) Steel production  years of  4.32 (2.0) NE) number of alcoholic  correlated with executive functions and 
plant (NE) exposure (E) IBLh: 4,613.5  drinks per week/grams visuospatial abilities
(Austria Lead  (4,187.6) (E) of alcohol per week Executive functioning and visuospatial 
Study) Battery of tests— abilities differed signiﬁcantly between 
5 domains exposed and control groups
Continued, next pagebone lead stores; b) the error in measurement
of tibia lead levels is larger than that for blood
lead; c) controlling for cross-sectional associa-
tions could obscure longitudinal ones; and
d) lead in blood reﬂects recent external expo-
sure, and is in equilibrium with bone lead
stores, possibly taking away explained vari-
ance from bone lead associations via this cor-
relation in cross-sectional analyses. 
Results of a cross-sectional analysis of
former organolead workers showed that
higher peak tibia lead levels (range, –2.2 to
105.9 µg/g) were related to poorer functioning
on a number of cognitive tests, including
those assessing manual dexterity, executive
ability, verbal intelligence, and verbal memory
(Stewart et al. 1999). In a longitudinal analysis
in this same population, among 535 lead
workers exposed a mean of 16 years before,
increases in peak tibia lead levels [mean
± SD = 22.6 ± 16.5 µg/g] but not in blood
lead levels predicted declines over time in
these same domains in addition to visual
memory (Schwartz et al. 2000). This ﬁnding
indicates that even many years after high lead
exposure, and in the absence of high current
lead exposure, cumulative lead dose may exert
progressive effects on cognitive functioning
(Links et al. 2001). 
Lead exposure and psychiatric symptoms.
Several lines of evidence suggest that
increased blood lead levels are associated with
psychiatric symptoms in adults, such as
depression, anxiety, irritability, and anger. For
example, a cross-sectional analysis of
107 occupationally exposed individuals
showed increased rates of depression, confu-
sion, anger, fatigue, and tension as measured
by the Profile of Mood States (POMS;
McNair et al. 1971) among those with blood
levels > 40 µg/dL (Baker et al. 1983).
Maizlish et al. (1995) found that current and
cumulative measures of blood lead levels in
currently exposed lead workers were associ-
ated with tension, anxiety, hostility, and
depression measured by the POMS question-
naire. Lindgren et al. (1996) examined the
POMS’ factor structure in retired lead smelter
workers and showed that the resulting “gen-
eral distress” factor was signiﬁcantly related to
IBL but not to current blood lead level.
Shih et al.
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Table 2. Continued.
% Male Race/ Primarily Lead dose Covariates
Sample mean age ethnicity Source of  current/ measure adjusted for
Author  size Design (SD) (%) Pb exposure past exposure mean (SD) outcome measures Summary of ﬁndings
Bleecker  254 XS 100  White  Canadian lead  Past  Blood: 27.7 (8.8) Age, educational  Signiﬁcant amount of variance in 
et al.  41 (9.4) 100 smelter  IBLa: 728.2 (434.4) achievement recognition and delayed recall accounted 
2005 (Canada  Lead  TWAb: 39.0 (12.3) Verbal learning and  for only by measures of IBL and TWA
Study) memory The “generalized memory impairment 
group” had the highest TWA and IBL 
compared with the “no impairment” and 
“retrieval difﬁculties” groups
Schwartz  576 with all  L 76 Asian  Battery, lead oxide  Current Blood: 31.4 (14.2) Age, education, sex,  Blood lead cross-sectionally was 
et al.  visits 41.4 (9.5)  100 or car radiator  Mean job  Tibia: 38.4 (43) height, BMI associated with lower executive ability 
2005  F/U: all  at visit 1 manufacturing duration:  Battery of tests— and manual dexterity scores
3 visits,  and secondary  8.5 (6.3) 9 domains Change in blood lead was associated with 
2 visits,  lead smelters  (71, 97, 150  longitudinal declines in few tests
1 visit =  (Korea Lead  no longer  Tibia lead was associated with 
72%, 16%,  Study) working in  longitudinal declines in manual dexterity, 
12% lead industry  executive abilities, neuropsychiatric and 
at visits 1,2,3) peripheral sensory function
Winker  48 (E) XS 100 NR Storage-battery  Past Blood lead:  Age, years of education,  Blood lead was correlated with 
et al. 2005  48 (NE) 39.6 (8.8) (E) plant (E) Mean of 5.2  5.4 (2.7) (E) verbal intelligence,  visuospatial abilities, attention, visual 
39.9 (8.8) (NE) Steel production  years since  4.7 (2.5) (NE) number of alcoholic  scanning, and visuomotor speed. IBL was 
plant (NE) last exposure IBLh:  drinks per week/grams  correlated only with choice reaction
(Austria Lead  4,153.3 (3,690.3) (E) of alcohol per week No differences between groups on 
Study) Battery of tests— neurobehavioral tests, and no 
5 domains differences between groups stratiﬁed by 
high IBL (> 4,500) vs. low IBL (< 4,500)
Dorsey  652 XS 77 Asian Battery, lead oxide  Current Blood: 30.9 (16.7) Series of four models  Ranked blood lead was associated with 
et al.  43.4 (9.6) 100 or car radiator  Mean job  Tibia: 33.5 (43.4) adjusting for age, sex,  executive ability, manual dexterity, and 
2006 manufacturing duration:  Patella: 75.1 (101.1) education, job duration,  PNS sensory function
and secondary  10 (6.5) height, BMI Ranked tibia lead was similar to blood 
lead smelters  Battery of tests— lead but also associated with 
(Korea Lead  14 neurobehavioral,  psychomotor speed
Study) 4 peripheral nervous  Ranked patella lead was associated with 
system measures, and  executive ability, manual dexterity, 
psychiatric symptoms depressive symptoms, and PNS sensory 
function. Adjustment for blood lead 
attenuated these associations
Winker  47 (E) XS 100 NR Storage-battery  Current Blood lead: Age Visuospatial abilities and executive 
et al.  48  39.5 (9.7) (E) plant (E) 11.7 (9.0)  30.8 (11.2) (E) Battery of tests— functioning performance decreased 
2006  (formerly E) 39.6 (8.8)  Storage-battery  mean years  5.4 (2.7) (Formerly E) 5 domains linearly from workers with short exposure 
(Formerly E) plant, police  of exposure  IBLh:  duration and long absence from 
ofﬁcers  duration 4,613.5 (4,187.6) (E) exposure, to the worst performing group 
(Formerly E) Past 4,153.3 (3,690.3) with long exposure and short/no absence 
(Austria Lead  5.26 (3.5)  (Formerly E) from exposure
Study) mean years 
since last 
exposure 
Abbreviations: APOE, apolipoprotein E; BMI, body mass index; CI, conﬁdence interval; E, exposed; F/U, follow-up rate; IQR, Interquartile range; L, longitudinal; MMSE, Mini-Mental State
Examination; NB, neurobehavioral; NE, nonexposed; Pb, lead; PNS, peripheral nervous system; OR, odds ratio; R, reference; XS, cross-sectional. 
Blood lead units: µg/dL; tibia/patella lead units: µg/g (unless noted otherwise). IBL: integrated blood lead calculated from blood measures during a time period, a measure of cumulative
dose: aµg-years/dL; gµmol-years/l; hµg-months/dL. TWA: time weighted average calculated by dividing IBL by number of years exposed, a measure of average intensity of lead exposure:
bµg/dL; fµmol/L. cCumPb: Area under the curve of blood lead levels over time: µg-years/dL. dCurrent and peak blood lead measured in units µmol/L. eCBLI: cumulative blood lead index:
product of blood lead and employment time: µmol-months/L.In occupationally exposed South Korean
lead workers, tibia lead levels were signiﬁcantly
associated with more depressive symptoms
measured by the Center for Epidemiologic
Studies Depression scale (CES-D; Radloff
1977) after adjusting for age, sex, education,
job duration, and blood lead level (Schwartz
et al. 2001). However, only one recent study
has examined a direct measure of cumulative
dose with bone measurements in a community
sample (Rhodes et al. 2003). These authors
used the Brief Symptom Inventory (BSI;
Derogatis and Melisaratos 1983) to show that
patella bone lead levels were associated with an
increased risk of anxiety and depression sub-
scale scores. The logistic regression estimate for
the phobic anxiety subscale was statistically sig-
niﬁcant (p < 0.05), as well as for the combined
measure of all three BSI subscales (anxiety,
depression, and phobic anxiety). 
Psychiatric symptoms, specifically symp-
toms of depression, potentially share the same
neural substrates with components of cogni-
tion, and thus may be important to late-life
cognitive functioning. Compared with nonde-
pressed elderly individuals, depressed elderly
perform more poorly on tests involving atten-
tion, memory encoding, and retrieval.
However, intelligence tests are more resistant
to these effects of depression (Arnett et al.
1999; Naismith et al. 2003; Weingartner et al.
1981). Depressive symptoms (as measured by
the CES-D) are positively associated with
both the risk of Alzheimer disease and a
steeper rate of cognitive decline (Wilson et al.
2002). Because late-life symptoms of depres-
sion are closely associated with dementia,
investigators have put forth a number of
hypotheses that suggest depression a) may be
a risk factor for cognitive decline, b) has risk
factors in common with dementia, c) is an
early reaction to declining cognition, and
d) inﬂuences the threshold at which dementia
emerges [for review see Jorm (2000)]. The
exact temporal and mechanistic relation
remains unclear. Regardless of the exact rela-
tion between depressive symptoms and cogni-
tive function, however, the assessment of the
impact of lead exposure on these outcomes is
not compromised. Whatever the associations
with these outcomes, they would still be
attributed to lead—that is, even if depressive
symptoms lead to worse cognitive perfor-
mance, and lead leads to symptoms of depres-
sion, the cognitive impairment as a result of
that depression could still be considered part
of the total effect of lead.
Lead–gene interactions. In the former
organolead worker studies discussed above,
possessing at least one apolipoprotein E
(APOE) ε4 allele magnified the negative
cross-sectional association of tibia lead levels
with performance on the cognitive domains
of executive ability, manual dexterity, and
psychomotor skills (Stewart et al. 2002). No
direct effects of the APOE ε4 allele were
observed on cognitive function in this study,
presumably because of the sample’s younger
age (range, 41–73 years). Other studies have
found that APOE ε4 modiﬁes dementia out-
come in individuals with previous traumatic
head injury, suggesting that APOE ε4 plays a
role in recovery from brain insults (Mayeux
et al. 1995), which may be extended to
include insult from lead exposure. 
Discussion
Summary of evidence for a causal relationship.
The literature on associations of recent and
cumulative dose biomarkers with cognitive
function has grown impressively since the
1995 review (Balbus-Kornfeld et al. 1995). We
believe sufficient evidence exists to conclude
that there is an association between lead dose
and decrements in cognitive function in adults.
Overall, while the association between blood
lead levels and cognitive function is more pro-
nounced in occupational groups with high cur-
rent lead exposures, associations between bone
lead levels and cognitive function are more
evident in studies of older subjects with lower
current blood lead levels, particularly in
longitudinal studies of cognitive decline. 
Consistency of associations. Following is
a summary of the findings from each of the
three types of populations. First, cross-sec-
tional studies of currently exposed lead work-
ers showed that associations of blood lead
levels and cognitive function were clearer than
the associations for tibia, patella, or calcaneus
lead levels, perhaps because the acute effects of
recent dose in an occupational setting masked
the chronic effects of cumulative lead dose.
Second, previously exposed occupational pop-
ulations demonstrated a stronger association
between cumulative lead dose measured in
tibia bone with cognitive deficits compared
with blood lead levels. The two studies that
deviated from these otherwise consistent ﬁnd-
ings may not have had sufficient power to
detect any associations (n < 60). Last, studies
of environmentally exposed adults who had
notably higher exposures in the past suggest
that bone lead level is more consistently associ-
ated with performance on cognitive tests than
is blood lead level. The domains associated
with lead dose do not differ in general by lead
biomarker (blood, tibia, patella). The cogni-
tive domains consistently associated with each
biomarker in both environmental and occupa-
tional studies on adults include verbal and
visual memory, visuospatial ability, motor and
psychomotor speed, manual dexterity, atten-
tion, executive functioning, and peripheral
motor strength. Comparisons of lead and psy-
chiatric symptom associations in previously
and currently exposed samples lend credence,
although perhaps at higher thresholds than for
cognitive outcomes, that neurobehavioral
functioning is consistently associated with
blood lead when exposure is currently high
(e.g., occupational) and bone lead when expo-
sure is primarily from past chronic exposure. 
These associations exist in multiple
settings, including both occupational and non-
occupational, in men and women, and in pop-
ulations with diversity by socioeconomic status
and race/ethnicity. This reduces the likelihood
of associations by statistical chance or due to
unmeasured confounding. However, this con-
sistency cannot completely rule out the possi-
bility of uncontrolled confounding or effect
modification (Martin et al. 2006; Shih et al.
2006). In addition, in studies of general popu-
lations with diversity by socioeconomic status
and race/ethnicity, the ability to disentangle
social, cultural, and biological factors from the
“independent” inﬂuence of lead dose may be a
futile exercise (Weiss and Bellinger 2006). 
Strength of association. The strength of
associations between lead and cognitive func-
tion is strong and can be compared to the
influence of age on cognitive function. The
comparative magnitude of these effects has
been reported in several studies. In currently
exposed lead workers, cross-sectional associa-
tions showed that a 5-µg/dL increase in blood
lead was equivalent to an increase of
1.05 years in age (Schwartz et al. 2001). The
magnitude of cross-sectional associations with
tibia lead levels in the BMS was moderate to
large. A proportion comparison of the direct
effect of age and the direct effect of tibia lead
levels on cognitive outcomes demonstrated
that the magnitude of the association with
tibia lead levels was moderate to large, equiva-
lent to 22–60% of the magnitude of the age
effect in its relations with cognitive domain
scores. Specifically, an interquartile range
increase in tibia lead levels was equivalent to
2–6 more years of age at baseline across all
seven domains (Shih et al. 2006). 
Longitudinal analyses in the NAS observed
that an interquartile range higher patella lead
level was approximately equivalent to that of
aging 5 years in relation to the baseline
MMSE score (Weisskopf et al. 2004) and an
interquartile range higher bone (patella or
tibia, depending on the speciﬁc cognitive out-
come) lead level was approximately equivalent
to that of aging 1 year in relation to the base-
line test scores on a battery of cognitive tests
(Weisskopf et al. 2007).
Specificity. Lead has adverse effects on
many other health outcomes in addition to
cognitive function. This is not surprising
given lead’s numerous biologic effects, includ-
ing calcium agnonism and antagonism
(Ferguson et al. 2000), binding to sulfhydryl
and carboxyl groups on proteins, and activa-
tion of nuclear transcription factors (Ramesh
et al. 2001), for example. It is thus not
Blood lead, bone lead, and adult cognitive function
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the brain and we do not believe this lack of
target organ specificity diminishes the infer-
ence for a causal relationship between lead
and cognitive dysfunction. 
Temporal relationship. Associations
between lead biomarkers and cognitive out-
comes have been demonstrated in both cross-
sectional and longitudinal studies. In several of
the longitudinal studies, change in cognitive
function was explicitly modeled in relation to
preceding lead dose or in relation to change in
lead dose. In either case, the temporality con-
dition is met. In addition, as bone lead is a
measure that ascertains prior dose, even in
cross-sectional analyses, analysis of bone lead
with cognitive test scores evaluates lead dose
that preceded current cognitive performance;
thus, while cognitive assessment is cross-
sectional, dose assessment is retrospective and
cumulative. This again would minimize
concerns about incorrect temporal relations. 
Biological gradient (dose–effect relations).
Nearly all reviewed studies found a dose–effect
relation for blood lead, bone lead, or both.
Existing studies do not allow determination of
a threshold dose for either blood lead or bone
lead or the shape of the dose–effect relationship
at low dose levels. Associations have been
observed in populations with mean blood lead
levels as low as 4.5 µg/dL (Wright et al. 2003)
and mean tibia lead levels as low as 18.7 µg/g
(Shih et al. 2006).
Biologic plausibility and experimental
data. Lead adversely affects the brain in a vari-
ety of ways. Lead is thought to increase oxida-
tive stress, induce neural apoptosis, inﬂuence
neurotransmitter storage and release, and
damage mitochondria. The ability of lead to
substitute for calcium allows it to affect cal-
cium-mediated processes and pass through
the blood–brain barrier. It may also interfere
with zinc-dependent transcription factors,
altering the regulation of genetic transcription
(Zawia et al. 2000). Animal studies indicate
that the accumulation of lead in the brain is
generally uniform (Widzowski and Cory-
Slechta 1994), although the hippocampus
and limbic system, prefrontal cerebral cortex,
and cerebellum are clearly principal sites of
the effects of lead (Finkelstein et al. 1998).
Low lead levels in rats produce structural
changes in the hippocampus (Cory-Slechta
1995), a brain region critical for learning and
memory (Eichenbaum 2001), which is consis-
tent with the ﬁnding of learning and memory
deﬁcits in lead-exposed individuals. 
Blood lead level is a measure of current
biologically active lead burden and is there-
fore a better marker of the acute effects of
recent lead dose. These are likely to be effects
on neurotransmission and calcium enzyme-
dependent processes such as synaptic plastic-
ity. This could lead to circulating blood lead
impairing, for example, information storage
and retrieval mechanisms or processing speed,
which have been suggested to impair perfor-
mance on cognitive tests (Salthouse 1996a,
1996b). Lead levels in bone are a measure of
cumulative dose over decades as well as a
source of lead in the body that is available for
mobilization into blood, especially during
periods of increased bone turnover (e.g., preg-
nancy, puberty). Although lead stored in
bone is not directly harmful to the brain, the
cumulative effects of chronic lead exposure
are likely to be related to oxidative stress and
neuronal death and could impair cognitive
function, for example, by reducing the capac-
ity of speciﬁc regions to process information,
or by impairing diffuse ascending projection
systems such as the midbrain cholinergic and
dopaminergic cells. 
Lead may also inﬂuence cognitive function
indirectly through its effects on blood pres-
sure, hypertension, or homocysteine levels.
Increased homocysteine levels, a well-known
risk factor for cardiovascular disease, have also
been associated with risk for poorer cognitive
functioning (Dufouil et al. 2003; Schafer et al.
2005a) and risk for dementia (Hogervorst
et al. 2002; McCaddon et al. 2003; Selley
2003). Homocysteine is neurotoxic to the cen-
tral nervous system by inﬂuencing neurotrans-
mitter synthesis, and causing excitotoxicity
and cell death (McCaddon and Kelly 1992;
Parnetti et al. 1997). Blood lead levels were
associated with homocysteine levels as well,
although the direction of causality has yet to be
determined (Guallar et al. 2006; Schafer et al.
2005b). Both blood and bone lead levels have
been linked with blood pressure and hyperten-
sion in community-based samples of older
adults (Martin et al. 2006; Nash et al. 2003)
and occupationally exposed populations (Glenn
et al. 2003, 2006). Hypertension has also been
identiﬁed as a potential risk factor for dementia
(Birkenhager and Staessen 2006; Hayden et al.
2006; Skoog and Gustafson 2006). Thus, lead
may indirectly play a role in cognitive declines
by way of poor vascular health. 
We believe the effect modification by
APOE genotype offers strong biologic plausi-
bility to the inference that lead causes cognitive
dysfunction (Stewart et al. 2002). The
APOE ε4 allele is a risk factor for late-onset
Alzheimier disease (Corder et al. 1993; Meyer
et al. 1998; Saunders et al. 1993), hippocampal
atrophy (Moffat et al. 2000), and senile
plaques (Zubenko et al. 1994). It appears that
the APOE ε4 allele lowers the age of onset of
the disease and accelerates age-related cognitive
decline (Meyer et al. 1998). Mechanistically,
APOE ε4 is involved in the recovery response
of injured nerve tissue (Poirier and Sevigny
1998), with the APOE ε4 allele having reduced
ability to promote growth and reduced antioxi-
dant properties (Miyata and Smith 1996; Teter
et al. 1999; Yankner 1996). The interaction of
APOE genotype with tibia lead level may be
related to an impaired ability to counteract
injury from lead exposure among APOE ε4
carriers. 
Another recent study also offers biologic
plausibility. In the former organolead workers,
tibia lead level was associated with the preva-
lence and severity of white matter lesions on
brain MRI, using the Cardiovascular Health
Study white matter grading system (Stewart
et al. 2006). Tibia lead level was also associ-
ated with smaller volumes on several regions
of interest ranging from large (e.g., total brain
volume, lobar gray and white matter volumes)
to small (e.g., cingulate gyrus, insula, corpus
callosum). As volume can decline because of
changes in cell number, synaptic number or
density, or other changes in cellular architec-
ture, these findings reinforce evidence that
lead may cause a persistent change in the brain
that is associated with progressive declines in
cognitive function. 
Public health implications. The removal
of lead from gasoline, paint, and most other
commercial products has succeeded in dra-
matically reducing environmental sources of
lead exposure, and this has been reﬂected by
the parallel declines in mean blood lead levels
in Americans over the same time frame.
However, lead has accumulated in the bones
of older individuals, and especially those of
lead workers exposed at the continued higher
levels encountered in lead-using workplaces.
Thus, past use of lead will continue to cause
adverse health effects even when current
exposures to lead are much lower than in the
past. Lead in bone is not directly harmful to
the central nervous system, and most of the
structural and neurochemical damage is likely
to have occurred decades ago. Nevertheless,
lead in bone might serve as a source from
which lead can be mobilized into blood, and
potentially cross the blood–brain barrier. The
chronic effects of lead may account for a pro-
portion of cognitive aging; future research
will be able to determine whether the chronic
effects of cumulative lead dose alter the trajec-
tory of normal cognitive aging. Research
efforts should be directed to development of
preventive interventions for both lead-associ-
ated cognitive decline with aging from past
exposures, as well as the mobilization of
current bone lead stores into the circulatory
system leading to new health effects. 
Cognitive aging occurs in conjunction
with the normal biological aging process. It
remains to be determined whether lead affects
cognitive aging in adults by permanently
reducing brain circuitry capacity thereby low-
ering baseline cognitive functioning, or by
inducing steeper declines in cognitive func-
tioning, leading to abnormal cognitive aging.
It may be that lead inﬂuences cognitive health
Shih et al.
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toms, hypertension, or homocysteine levels, all
of which inﬂuence cognitive impairment and
risk of dementia. Future investigations should
explicitly account for these complex causal
pathways, and also determine whether chronic
effects of cumulative lead dose increases the risk
for such clinically relevant syndromes as mild
cognitive impairment (Petersen et al. 1999).
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